These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30755019)

  • 1. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
    Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
    Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
    Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract]   [Full Text] [Related]  

  • 3. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M
    Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors and lower limb complications: an updated meta-analysis.
    Lin C; Zhu X; Cai X; Yang W; Lv F; Nie L; Ji L
    Cardiovasc Diabetol; 2021 Apr; 20(1):91. PubMed ID: 33910574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Nov; 193(45):E1746-E1749. PubMed ID: 34782384
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
    Skelley JW; Carter BS; Roberts MZ
    Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 11. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
    Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Rose JB; Sorabji D; Bajaj HS
    Can J Diabetes; 2019 Oct; 43(7):464-471. PubMed ID: 31133438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2020 Jan; 12(1):8-9. PubMed ID: 31722441
    [No Abstract]   [Full Text] [Related]  

  • 17. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
    Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin: increased risk of toe amputations? Do not use this drug in diabetes.
    Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30645831
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
    Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW
    Am Heart J; 2021 Mar; 233():141-148. PubMed ID: 33358942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.